Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. (31st December 2022)

• Record Type: Journal Article
• Authors: Belamkar, Aditya; Harris, Alon; Zukerman, Ryan; Siesky, Brent; Oddone, Francesco; Verticchio Vercellin, Alice; Ciulla, Thomas A.
• Is Part Of: Annals of medicine. Volume 54:Number 1(2022)
• Page Start: 343
• Page End: 358
• Publication Date: 2022-12-31
• Subjects: Glaucoma -- glaucoma treatment -- topical therapy -- sustained release -- adherence -- nanotechnology; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2021.1955146
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness. The disease has conventionally been characterized by an elevated intraocular pressure (IOP); however, recent research has built the consensus that glaucoma is not only dependent on IOP but rather represents a multifactorial optic neuropathy. Although many risk factors have been identified ranging from demographics to co-morbidities to ocular structural predispositions, IOP is currently the only modifiable risk factor, most often treated by topical IOP-lowering medications. However, topical hypotensive regimens are prone to non-adherence and are largely inefficient, leading to disease progression in spite of treatment. As a result, several companies are developing sustained release (SR) drug delivery systems as alternatives to topical delivery to potentially overcome these barriers. Currently, Bimatoprost SR (Durysta TM ) from Allergan plc is the only FDA-approved SR therapy for POAG. Other SR therapies under investigation include: bimatoprost ocular ring (Allergan) (ClinicalTrials.gov identifier: NCT01915940), iDose ® (Glaukos Corporation) (NCT03519386), ENV515 (Envisia Therapeutics) (NCT02371746), OTX-TP (Ocular Therapeutix) (NCT02914509), OTX-TIC (Ocular Therapeutix) (NCT04060144), and latanoprost free acid SR (PolyActiva) (NCT04060758). Additionally, a wide variety of technologies for SR therapeutics are under investigation including ocular surface drug delivery systems such as contact lenses and nanotechnology. While challenges remain for SR drug delivery technology in POAG management, this technology may shift treatment paradigms and dramatically improve outcomes. Graphical Abstract: UF0001